sfa 17:0

SFA 17:0, scientifically known as heptadecanoic acid and commonly referred to as margaric acid, is a saturated fatty acid with an odd number of carbon atoms (17:0). Unlike the more abundant even‑chain saturated fatty acids such as palmitic (16:0) or stearic acid (18:0), odd‑chain fatty acids like C17:0 occur in relatively small amounts in foods and human tissues. Their rarity and unique chemical structure have long made them of special interest in nutritional biochemistry and metabolic research. Margaric acid is composed of a 17‑carbon chain with no double bonds, classifying it as fully saturated. Historically, odd‑chain fatty acids were considered metabolic curiosities and were often used as internal standards in analytical chemistry rather than as nutrients. Modern lipidomics and population‑based studies, however, have re‑energized interest in C17:0, particularly as a nutritional biomarker of dairy fat intake and potential correlate of metabolic health. The molecule itself is a waxy solid at room temperature and is incorporated into triglycerides within animal fats, especially those from ruminant animals such as cows, sheep, and goats. While C17:0 is present in the diet, it can also be formed endogenously via metabolic pathways involving short‑chain fatty acids like propionate produced by the gut microbiome, complicating the interpretation of circulating levels in blood. Notably, major health authorities such as the NIH Office of Dietary Supplements and other guideline bodies have not established recommendations for C17:0 intake because it is not considered an essential nutrient with a defined deficiency syndrome. Instead, nutritional interest often centers on how circulating levels of C17:0 reflect broader dietary patterns, particularly intake of whole‑fat dairy and related foods, and how those patterns relate to health outcomes revealed in epidemiological research.

While SFA 17:0 is not classified as an essential nutrient with specific physiological functions like vitamins or minerals, it plays an important role as a biomarker in nutritional epidemiology and is increasingly studied for its associations with health outcomes. A substantial body of observational research indicates that higher circulating concentrations of odd‑chain saturated fatty acids, including C17:0, are associated with lower risks of cardiometabolic conditions such as type 2 diabetes and metabolic syndrome. For example, a recent cross‑sectional analysis reported that individuals with higher erythrocyte membrane levels of C17:0 had significantly lower odds of metabolic syndrome, with a strong inverse association that was partially mediated by improved insulin sensitivity. This suggests that elevated levels of C17:0 may coincide with metabolic profiles less prone to insulin resistance. Although mechanistic studies are still emerging, one interpretation is that odd‑chain fatty acids reflect broader dietary and microbial metabolic patterns. Higher C17:0 levels often correlate with greater intake of fermented dairy products and adequate dietary fiber, which supports gut bacterial fermentation and propionate production, a precursor for endogenous odd‑chain fatty acid synthesis. These dietary patterns are themselves linked to lower cardiometabolic risk, making it difficult to disentangle whether C17:0 directly influences physiology or serves as a surrogate marker for healthier diets. Importantly, the evidence supporting direct causal benefits remains limited, and controlled interventional studies have not conclusively demonstrated that increasing dietary C17:0 alone improves health outcomes independent of other dietary factors. Nevertheless, the consistent observational associations across numerous cohorts provide compelling grounds for further research into the potential roles of odd‑chain fatty acids in metabolic regulation. Current evidence highlights that while consuming foods rich in C17:0 contributes to circulating levels, overall dietary patterns emphasizing whole foods and high fiber likely drive the most meaningful health benefits rather than the fatty acid itself in isolation.

There are no established dietary reference intakes (DRIs), Recommended Dietary Allowances (RDAs), or Adequate Intakes (AIs) for SFA 17:0 from major nutrition authorities, including the NIH Office of Dietary Supplements, because it is not classified as an essential nutrient. Unlike vitamins and minerals that have clear physiological functions and deficiency syndromes, odd‑chain saturated fatty acids like C17:0 do not meet criteria for essentiality, and deficiency states have not been characterized in clinical settings. In the absence of formal requirements, research studies often report circulating concentrations rather than intake targets. Circulating levels of C17:0 can vary widely depending on diet and individual metabolism, reflecting both dietary intake and endogenous synthesis from gut‑derived propionate. Population studies have noted that typical Western diets yield modest amounts of C17:0 from foods, and higher circulating levels are often found in individuals with greater intake of fermented dairy and adequate fiber. Some research describes dietary patterns associated with higher C17:0 intakes as part of broader healthy eating patterns rather than focusing on specific gram targets for C17:0 alone. Because total saturated fat has recognized effects on lipids, general dietary guidance from major health organizations recommends limiting saturated fat intake to a defined percentage of daily calories to reduce cardiovascular risk. While C17:0 constitutes a small fraction of total saturated fats in foods, focusing on balanced diets with appropriate fat quality—favoring unsaturated fats and whole foods—remains the cornerstone of dietary recommendations. For individuals interested in monitoring or modifying circulating levels of C17:0, clinicians may consider evaluating overall dietary patterns that include fermented dairy and adequate fiber rather than aiming for specific C17:0 intake amounts. Ultimately, without established requirements or upper limits, it is prudent to view C17:0 intake through the lens of total diet quality and cardiovascular risk management.

Because sfa 17:0 is not classified as an essential nutrient, there are no defined clinical deficiency syndromes attributable specifically to inadequate intake. Unlike vitamins such as vitamin C (scurvy) or vitamin D (rickets), odd‑chain saturated fatty acids like C17:0 do not have recognized physiological functions that, when absent, cause overt deficiency diseases. Circulating levels can be measured in plasma or erythrocyte membranes, but low levels are interpreted as markers of dietary patterns rather than signs of nutrient deficiency. For example, low circulating C17:0 may reflect low intake of dairy fat or inadequate fermentation of dietary fiber by gut microbiota, rather than a pathological lack of a required nutrient. In nutritional research settings, individuals with low C17:0 plasma concentrations often exhibit dietary patterns lacking fermented dairy and high‑fiber foods, which correlate with higher cardiometabolic risk. As such, low levels are associated with less favorable metabolic profiles such as higher insulin resistance or increased incidence of metabolic syndrome in some observational studies. These associations do not signify deficiency in the clinical sense but rather highlight population‑level correlations. Because C17:0 can also be endogenously synthesized from propionate—produced by bacterial fermentation of fiber in the gut—variations in microbiome composition and dietary fiber intake can influence circulating levels independent of direct dietary intake. Therefore, what might be deemed 'low' C17:0 in a biomarker study should be interpreted in the context of overall diet quality, microbiome health, and cardiometabolic profile rather than as a deficiency requiring correction. Clinicians and researchers typically focus on established nutritional markers and cardiometabolic risk factors—such as lipid profiles, glucose metabolism, and inflammatory markers—when assessing nutrition status and health, rather than on C17:0 levels alone.

SFA 17:0 occurs in foods that contain animal fats, especially those from ruminant animals. Because odd‑chain fatty acids represent a small fraction of total fatty acids in foods, their contributions are modest compared to major macronutrients, but specific foods can be ranked by their relative content. Based on comprehensive nutrient ranking tools and food composition databases, the following foods contain measurable amounts of heptadecanoic acid (17:0). Data from nutrient ranking sources indicate that animal products with higher total fat content typically contain more C17:0. Foods such as fatty cuts of beef and lamb, processed meats, and dairy products are among the richer sources. For example, fast foods with hamburger patties often appear high on lists because of the combined contributions of beef fat and condiments. Whole‑fat dairy such as full‑fat Greek yogurt and ricotta cheese contain moderate amounts, reflecting milk fat content. Heavy whipping cream and various cheeses also provide measurable amounts. In contrast, lean meats and low‑fat products contain less because total fat content impacts C17:0 quantity. While plant foods contain negligible amounts of C17:0, dietary patterns that include fermented dairy and higher fiber may influence endogenous odd‑chain fatty acid synthesis via microbial propionate production. When considering food sources, it is important to balance the desire for odd‑chain fatty acids with overall dietary patterns, given the broader implications of saturated fat on cardiovascular health. Replacing some animal fats with unsaturated fat sources and emphasizing whole, nutrient‑dense foods aligns with public health guidance while still allowing for moderate consumption of foods that provide C17:0 as part of an overall balanced diet.

As a component of dietary fat, SFA 17:0 is absorbed along with other long‑chain fatty acids in the small intestine via micelle formation facilitated by bile acids. Once absorbed, long‑chain fatty acids are incorporated into chylomicrons and transported via the lymphatic system into circulation. Because SFA 17:0 is structurally similar to other saturated fats, it does not require specialized transport mechanisms, but its overall contribution to the fatty acid pool is small relative to more abundant fatty acids. Bioavailability of dietary fats depends on overall fat intake and digestive efficiency; individuals with malabsorption syndromes or impaired bile production may have reduced absorption of long‑chain fats. Endogenous production of odd‑chain fatty acids complicates interpretation of circulating levels because gut‑derived propionate, produced by bacterial fermentation of dietary fiber, can serve as a precursor for odd‑chain fatty acid synthesis in the liver. Thus, circulating 17:0 levels reflect both dietary intake and microbiome activity rather than bioavailability alone. Factors that influence absorption and subsequent metabolism include overall diet composition, fat intake patterns, and the health of the gastrointestinal tract.

Standalone supplements of purified C17:0 are uncommon and not widely studied in humans. Because it is not an essential nutrient with established requirements or deficiency syndromes, supplementation for the purpose of raising C17:0 levels is not routinely recommended. Nutritional research suggests that higher circulating levels are associated with healthier metabolic profiles, but these associations have not been translated into evidence supporting supplementation for disease prevention. Furthermore, intentionally consuming large amounts of saturated fats to raise C17:0 intake could adversely affect lipid profiles, particularly LDL‑cholesterol, in susceptible individuals. Therefore, dietary patterns emphasizing fermented dairy and adequate fiber—rather than supplements—are more consistent with achieving balanced nutrition and cardiovascular health. Individuals considering supplements should consult healthcare professionals, especially if they have lipid disorders or cardiometabolic risk factors.

No specific toxicity data or tolerable upper intake level exists for SFA 17:0 itself. However, saturated fats as a class have recognized effects on cardiovascular risk, primarily through their influence on LDL‑cholesterol levels. Major health organizations generally recommend limiting saturated fat intake within context of total energy consumption to reduce cardiovascular risk. Excessive intake of saturated fats can contribute to unfavorable lipid profiles and increased heart disease risk. Therefore, focusing on balanced intake of fats, prioritizing unsaturated fats, and moderating foods high in saturated fat is prudent.

There are no specific drug interactions documented for SFA 17:0 itself. However, drugs that target lipid metabolism—such as statins, fibrates, and bile acid sequestrants—can modify fatty acid profiles and lipid levels. Individuals on lipid‑lowering medications should discuss dietary fat intake with their clinicians to ensure appropriate management of cardiovascular risk.